Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07223814

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

The current standard of care treatment for adult patients with acute myeloid leukemia (AML) consists of chemotherapy and, if indicated, donor stem cell transplantation.

Bleximenib blocks the interaction between a protein called menin and another protein called KMT2A in the leukemia cells. When this interaction is disrupted in AML with mutations in the NPM1 or KMT2A gene, bleximenib can cause leukemia cells to die.

The main objective is to assess if treatment with bleximenib, when added to chemotherapy treatment will improve treatment outcome in adult participants with newly diagnosed AML who present with mutations in the NPM1 or KMT2A genes.

This is a randomized, double-blind, placebo-controlled, phase 3 clinical trial. All of the participants will receive standard chemotherapy treatment, combined with either bleximenib or a placebo. A placebo is a substance that looks like the study medicine but has no active ingredients (e.g., a sugar pill). In a double blind trial neither the participant nor the doctor know if placebo or active study drug is given.

After the end of the protocol treatment there will be an observational follow-up of 4 years from the time of inclusion of the last patient. The results of the different treatment groups will be compared.

875 previously untreated patients with AML with a specific change in the DNA of the leukemia cells (a KMT2A rearrangement or a NPM1 mutation) will be included. Participants must be 18 years or older and considered eligible for intensive chemotherapy.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Acute Myeloid Leukemia Hematologic Diseases Hemic and Lymphatic Diseases Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Neoplasms Neoplasms by Histologic Type

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

AU-Adelaide-FLINDERS, Adelaide, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥18 years of age (or the legal age of majority in the jurisdiction in which the study is taking place, whichever is greater) at the time of informed consent.
  • New diagnosis of AML (≥10% blasts in BM or peripheral blood) with mutated NPM1 or with recurring rearrangements involving KMT2A according to ICC 2022 criteria.
  • Considered eligible for intensive chemotherapy.
  • WHO/ECOG performance status ≤2.
  • Adequate renal and hepatic functions prior to randomization.

Exclusion criteria

  • Prior (chemo-)therapy for AML, including prior treatment with hypomethylating agents
  • Known active leukemic involvement of the central nervous system (CNS).
  • Recipient of solid organ transplant.
  • Cardiac disease:
  • Any of the following within 6 months of randomization: myocardial infarction, uncontrolled/unstable angina, congestive heart failure (NYHA Class III or IV), uncontrolled or symptomatic arrhythmias, stroke, or transient ischemic attack.
  • QTc interval using Fridericia's formula (QTcF) ≥470 ms. Prolonged QTc interval associated with bundle branch block or pacemaking is permitted.
  • Left ventricular ejection fraction (LVEF) <40% by ECHO or MUGA scan obtained within 28 days prior to the start of study treatment.
  • Previously received cumulative dose of any combination of anthracyclines or anthracenediones of ≥500 mg/m2.
  • Chronic respiratory disease requiring supplemental oxygen.

Treatment and study plan

Bleximenib

Drug

Participants will receive bleximenib

Cytarabine

Drug

Participants will receive Cytarabine

Daunorubicin or Idarubicin

Drug

Participants will receive Daunorubicin or Idarubicin

Placebo

Drug

Participants will receive Placebo

Primary outcomes

  1. Event-Free Survival (EFS) in adult patients with newly diagnosed NPM1m or KMT2Ar AML eligible for intensive chemotherapy

    Time frame: Up to 4 years and 5 months

    To assess if treatment with bleximenib, as compared with placebo, in combination with remission induction chemotherapy, prolongs event-free survival (EFS) measured from the time from randomization to failure to achieve CR after remission induction, hematologic relapse after achieving CR, or death, whichever occurs first.

Secondary outcomes

  1. Overall Survival (OS) in adult patients with newly diagnosed NPM1m or KMT2Ar AML eligible for intensive chemotherapy

    Time frame: Up to 7 years and 10 months

    To assess if treatment with bleximenib, as compared with placebo, in combination with remission induction and consolidation chemotherapy, followed by maintenance therapy, prolongs overall survival (OS) measured from randomization to death due to any cause.

  2. Rates of CR, CRh, CRi in adult patients with newly diagnosed NPM1m or KMT2Ar AML eligible for intensive chemotherapy

    Time frame: Up to 7 years and 10 months

    Defined as the proportion of participants achieving a given response after induction cycle 1 and after induction cycle 2.

  3. Prolongation of CR (DoCR) in adult patients with newly diagnosed NPM1m or KMT2Ar AML eligible for intensive chemotherapy

    Time frame: Up to 4 years and 5 months

    Defined as the time from achieving first response of CR to hematologic relapse or death from any cause, whichever occurs first.

  4. Percentage of participants undergoing an allo-SCT in adult patients with newly diagnosed NPM1m or KMT2Ar AML eligible for intensive chemotherapy

    Time frame: Up to 7 years and 10 months

    To assess the percentage of participants undergoing an allo-SCT as part of protocol treatment

Study contacts

Contact information is provided by the study sponsor or research team.

M.H.G.P. Raaijmakers

CONTACT

[email protected]

010 7033740

Sponsors and collaborators

Lead sponsor

Stichting Hemato-Oncologie voor Volwassenen Nederland

Other

Collaborators

  • German-Austrian Acute Myeloid Leukemia Study Group

Registry information

Official study title

Bleximenib or Placebo in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for the Treatment of Patients With Newly Diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: a Double-blind Phase 3 Study

Important dates

Study start
2026
Primary completion
2030
Study completion
2033
First posted
Nov 3, 2025
Registry last updated
Jul 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.